Milsaperidone (VHX-896) vs Quetiapine (Seroquel)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Quetiapine (Seroquel)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00305422 · Phase 3 · completed

The study was randomized and double-blinded with an active risperidone comparator, but its small sample of 45 participants limits the strength of the evidence. The primary comparison was not reported, and the primary focus included cognitive and functional brain-activation measures rather than a clearly specified hard clinical endpoint.

Next expected readout: February 2032 · NCT07152184 (registry estimate)

Reported efficacy

Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).

Result source: NCT00305422

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Quetiapine (Seroquel)
PANSS total, change—Not reported-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • -33.4 vs -35.9 wk 6 · n 159 · Phase 3 · primary NCT00882518
CGI-S, change—Not reported-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.8 vs -2.1 wk 6 · n 194 · Phase 3 · secondary NCT00882518
PANSS response—Not reported62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380
PSP, change—Not reported15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380
Relapse (% of patients)—Not reported—Not posted · NCT00305422

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel)
-24 vs -15.9−8.1 vs placebowk 6 · n 150NCT01810380
1 other result
  • -33.4 vs -35.9 wk 6 · n 159 · Phase 3 · primary NCT00882518

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel)
-1.4 vs -0.9−0.5 vs placebowk 6 · n 150NCT01810380
1 other result
  • -1.8 vs -2.1 wk 6 · n 194 · Phase 3 · secondary NCT00882518

PANSS response

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel)
62.7% vs 32.1%+30.6 vs placebowk 6 · n 150NCT01810380

PSP, change

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel)
15.3 vs 9.4+5.9 vs placebowk 6 · n 138NCT01810380

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Quetiapine (Seroquel)
—Not posted · NCT00305422
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Quetiapine (Seroquel): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricQuetiapine (Seroquel)
Dropout rate
—Seroquel IRa
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
30.4%
NCT00156715 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
20.8%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
19.4%
NCT00882518 · Phase 3 · registry result, not featured evidence
37.8%
NCT00227305 · Phase 3 · registry result, not featured evidence
16.7%
NCT00642369 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—Seroquel IRa
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
—Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
—
NCT00156715 · Phase 4 · registry result, not featured evidence
—Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
2.6%Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
4.6%
NCT00882518 · Phase 3 · registry result, not featured evidence
10.5%
NCT00227305 · Phase 3 · registry result, not featured evidence
6.7%
NCT00642369 · Phase na · registry result, not featured evidence
Serious AEs
0%Seroquel IRa
NCT01213836 · Phase 4 · registry result, not featured evidence
show 7 more results
0%Seroquel XR
NCT01213836 · Phase 4 · registry result, not featured evidence
18.8%
NCT00156715 · Phase 4 · registry result, not featured evidence
1.3%Quetiapine
NCT01810380 · Phase 3 · registry result, not featured evidence
—Quetiapine Extended Release
NCT01810380 · Phase 3 · registry result, not featured evidence
0%
NCT00882518 · Phase 3 · registry result, not featured evidence
12.1%
NCT00227305 · Phase 3 · registry result, not featured evidence
0%
NCT00642369 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
somnolence 3.2%
delusion 1.6%
dizziness 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
show 5 more results
psychotic disorder 1.6%
sedation 1.6%
sleep disorder 1.6%
NCT01213836 · Phase 4 · registry result, not featured evidence
dry mouth 43.8%
sedation 43.8%
increased appetite/weight gain 31.3%
NCT00156715 · Phase 4 · registry result, not featured evidence
somnolence 22.2% (placebo 5%)
weight increased 13.1% (placebo 3.7%)
dizziness 11.8% (placebo 0.6%)
NCT01810380 · Phase 3 · registry result, not featured evidence
constipation 25%
dizziness 14.3%
insomnia 12.8%
NCT00882518 · Phase 3 · registry result, not featured evidence
somnolence 30.3%
increased appetite 20%
sedation 18.9%
NCT00227305 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Quetiapine (Seroquel)

Attention Composite Z-score 0.002 standardised units
absolute change · standardised units
No placebo or comparator arm
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.098 standardised units
Post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
N-Back Task 2.875 score
absolute change · score
No placebo or comparator arm
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
show 1 more result
2.897 score
ONB post 1
NCT01213836 · Phase 4 · registry result, not featured evidence
Drinking Days Per 2.7 per week @ 12wk
absolute value · per week
No placebo or comparator arm
NCT00156715 · Phase 4 · registry result, not featured evidence
PANSS Total -24 vs -15.9 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
show 1 more result
-33.4 vs -35.9 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
CGI-S -1.4 vs -0.9 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.8 vs -2.1 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
CGI-I 2.5 vs 3 placebo score @ 6wk
absolute value · score
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale -8.1 vs -5.4 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
show 1 more result
-9.9 vs -11.1 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale -4.5 vs -3.1 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
show 1 more result
-5.9 vs -6.7 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -11.6 vs -8.2 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
show 1 more result
-12.9 vs -13.9 Chlorpromazine score @ 6wk
NCT00882518 · Phase 3 · registry result, not featured evidence
PANSS-EC -3.9 vs -2.5 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Negative -4.8 vs -3.6 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence
PANSS Marder Positive -8.4 vs -5.7 placebo score @ 6wk
absolute change · score
NCT01810380 · Phase 3 · registry result, not featured evidence

+ 12 further endpoints in the CSV export.

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Quetiapine (Seroquel)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05480150 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Available safety results

Quetiapine (Seroquel)

Dropout rate
37.8%
NCT00227305 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
10.5%
NCT00227305 · Phase 3 · registry result, not featured evidence
Serious AEs
12.1%
NCT00227305 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
somnolence 30.3%
increased appetite 20%
sedation 18.9%
NCT00227305 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Quetiapine (Seroquel)'s landscape